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a hypothesis that caveolae are abolished by Δ-24 DHCR 
intervention and it is revealed that these microdomains are 
vital EMT signalling structures for lung cells but not ER- 
and Ras-negative breast cells. When signalling by extra-
cellular signals is quenched by removal of the hydrophilic 
conduit provided by caveolae, the transcriptome responds 
by moving the cellular identity towards quiescence.
Keywords Caveolae · Metastasis · Gene expression · 
Proadifen · Statins
Introduction
The dissemination of solid tumour cell clones often pre-
cedes the detection of the primary cancer growth. The met-
astatic cascade is a multistep process beginning with infil-
tration through the organ of the primary tumour and into the 
blood stream (Talmadge and Fidler 2010). This stage has 
often occurred prior to first treatment [for example, 40 % 
of newly diagnosed patients with non-small lung cancer 
already have metastases (Goldstraw et al. 2007)], and it is 
therefore later steps of the cascade that represent opportu-
nities for useful chemotherapeutic intervention: specifically 
suppression of existing disseminated cells at a pre-aggres-
sive stage (Weber 2013). Typical anticancer drugs target 
replication and promote apoptosis, but these are ineffective 
strategies to kill latent clones and progress in this field has 
been impeded by a lack of validated predictive biomark-
ers for metastatic potential (Vignot et al. 2012). Angio-
genesis has been successfully targeted (Shojaei 2012) by 
drugs such as bevacizumab, but newer therapies targeting 
other phenotypic changes or intrinsic genetic or epigenetic 
markers are sought to combat metastasis (Lehembre and 
Regenass 2012). Cholesterol pathway inhibitors are often 
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Purpose Mevalonate pathway inhibitors are potentially 
useful chemotherapeutic agents showing growth inhibi-
tion and pro-apoptotic effects in cancer cells. The effects 
of statins and bisphosphonates on cancer growth are attrib-
uted to a reduction in protein isoprenylation. Post-transla-
tional modification and activation of GTPase binding Ras 
superfamily permit the recruitment of these signal proteins 
to membranes where they mediate the cancer phenotype. 
Here, the effects of three inhibitors of the mevalonate path-
way and one specific inhibitor of sterol regulatory element-
binding proteins were studied in both an ER-negative, Ras-
inactive breast (MDA-MB-231) and lung adenocarcinoma 
(CaLu-1) cells in vitro.
Methods Treated cells were subject to genome-wide gene 
expression profiling. A gene subset was established so that 
the epithelial to mesenchymal transition (EMT) could be 
observed and compared with signalling protein shifts.
Results Within the subset, some genes normally up-regu-
lated during EMT were asymmetrically reduced by a Δ-24 
DHCR inhibitor in the lung cells. Signalling proteins asso-
ciated with caveolae were down-regulated by this oxidore-
ductase inhibitor, while those associated with membrane 
rafts were up-regulated.
Conclusions This study decouples isoprenylation 
effects from cholesterol events per se. The data support 
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incidental inhibitors of the isoprenoid pathway and have 
been studied in the context of cell cycle arrest and apop-
tosis (Mo and Elson 2004), but their putative effects on the 
epithelial–mesenchymal transition (EMT) and metastasis 
per se have not been fully explained (Schech et al. 2013; 
Thurnher et al. 2013). Combination strategies using statins 
with prenyltransferase inhibitors display synergistic anti-
cancer effects (Konstantinopoulos and Papavassiliou 2007), 
and likewise, the bisphosphonates show synergism with 
farnesyl transferase inhibitors (Andela et al. 2002).
Paget’s ‘seed and soil’ theory (Paget 1989) indicates that 
disseminated cancer cells only fulfil their potential for inva-
sion and proliferation when they are able to adapt to their 
new environment. Distal metastases are under stress by 
their new microenvironment and by any systemic drug regi-
men—the response being either adaptive (Allen and Louise 
Jones 2011) or quiescent (Redmond et al. 2008). Quiescent 
cells, including micro-metastases, can remain dormant for 
years yet changes to the microenvironment can then trigger 
unrestrained proliferation and the re-emergence of disease 
(Mimeault and Batra 2010a, b). It is likely that MET ena-
bles the cell to re-acquire the signal processing apparatus 
that allows cognition of the microenvironment (Monteiro 
and Fodde 2010), and this research explores the hypothe-
sis that both EMT and MET are responsive to mevalonate 
pathway inhibitors in lung cells in a process that is inde-
pendent from protein isoprenylation.
EMT can be induced by extrinsic factors such as hepat-
ocyte growth factor, vascular endothelial growth factor, 
platelet-derived factor and others (Thiery et al. 2009). EMT 
cells are not only motile but also non-senescing and refrac-
tory to apoptosis-inducing treatments. Van Zijl calls this 
amoeboid phenotype ‘the ultimate exit strategy of cancer 
cells’ (van Zijl et al. 2011). A switch into MET is needed 
for the cell to undergo differentiation into the distal organ 
identity and lose the plasticity needed for invasion. The 
absence of extracellular matrix (ECM) recognition at this 
stage can cause the micrometastases to become dormant, 
and it is proposed that this cognition is inhibited by selec-
tive disruption of caveolae, at least in lung cells. The degree 
that Cav-1 protein is phosphorylated at Tyr14 of the amino 
terminus increases in response to signals and insulin, EGF, 
PDGF and Src-family kinases are implicated in this phos-
phorylation. It is known that depletion of cholesterol causes 
changes to caveolae formation and localisation, and these 
changes have been linked to nitric oxide synthase (NOS) 
activation (Everson and Smart 2001). It has been proposed 
that caveolae are a scaffold for eNOS as they are co-local-
ised. Over-expression of caveolin-1 has been observed to 
prevent statins and VEGF from stimulating NOS-mediated 
angiogenesis (Brouet et al. 2001).
Using four types of inhibitor, this study was designed 
to reveal the effects of multi-stage blockade of mevalonate 
and associated pathways on gene expression in two con-
trasting cancer cell lines. Caveolae have distinctive hydro-
philic interior and are entry points to some important 
growth factors, including hormones, and are thus a critical 
signalling conduit. This signalling was investigated using 
array techniques to determine whether caveolae could be 
specifically inhibited and to assess the effects of such an 
intervention on EMT.
Experimental
Sources
MDA-MB-231 cells were obtained from Cell Lines Ser-
vice, Eppenheim, Germany, and CaLu-1 cells were 
obtained from ECCAC, UK. Illumina Human HT12_
V4_0_R2_15002873_B human expression microarrays 
were purchased from Gen-Probe Ltd, UK, and University 
of Texas Medical School. RNeasy Maxi Kit was purchased 
from QIAGEN Ltd. All other reagents were sourced from 
Sigma Aldrich Ltd, UK, except where noted. The antibody 
array slides and associated reagents were purchased from 
Full Moon Biosystems Inc, USA.
Treatments
Pravastatin (as sodium salt hydrate), a hydrophilic statin, 
has previously been shown to have pro-apoptotic properties 
that are dependent upon inhibition of HMG-CoA reduc-
tase (Kato et al. 2010); proadifen hydrochloride (N,N-
diethylaminoethyl 2, 2-diphenylethanoate hydrochloride) 
is a Δ-24 dehydrocholesterol reductase (DHCR) inhibitor. 
Proadifen truncates the pathway at the distal desmosterol 
and lanosterol intermediates and prevents conversion of 
4,4-dimethylcholesta-8 (Thurnher et al. 2013), 24-dien-
3β-ol into 4,4-dimethylcholesta-8[9], 24-en-3β-ol, zymos-
terol into 7-dihydroxyzymesterol, 7,24-cholestadien-3β-ol 
into 7-cholesten-3β-ol and 5,7,24-cholestatrien-3β-ol into 
5,7-cholestadien-3β-ol.
Zoledronic acid monohydrate (Alfa Aesar Chemicals) 
was used as a typical bisphosphonate, and fatostatin is 
a specific inhibitor of sterol regulatory element-binding 
proteins (SREBPs). Zoledronic acid is an aminobisphos-
phonate prescribed for osteoporosis as it slows down bone 
reabsorption. It has also been used to suppress prenylation 
of GTPases and has anti-proliferative and anti-metastatic 
effects on MDA-MB-231 (Reinholz et al. 2002) and other 
cells. It has also been shown that zoledronic acid can 
reverse the EMT through inactivation of NF-κB in MDA-
MB-231 (Schech et al. 2013). Fatostatin is a diarylthiazole 
derivative inhibitor of SREBPs by binding to the escort 
protein SCAP (Kamisuki et al. 2009).
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Dose
Each treatment was prepared to the final concentration in 
fresh media for 24 h. The final concentrations of pravas-
tatin and proadifen in culture flasks were 8.0 µM and 
8.5 × 10−5 % (w/v), respectively. The dose of pravastatin 
was chosen because low millimolar serum levels are attain-
able in vivo at high doses (Wojtkowiak et al. 2011). Zole-
dronic acid was used at a final concentration of 100 µM, a 
dose chosen to enable direct comparison with a published 
data set (Vintonenko et al. 2012). Fatostatin hydrobromide 
was used at 10 µM after solubilisation in dimethyl sulfox-
ide in accordance with published work (Li et al. 2014).
Gene expression assays
MDA-MB-231 cells were grown to 80 % confluence in 
Dulbecco’s modified eagles medium (DMEM) supple-
mented with 10 % v/v foetal bovine serum (FBS), 4500 mg 
glucose/L 110 mg sodium pyruvate/L and l-glutamine prior 
to drug exposure. CaLu-1 cells were grown in supplemented 
minimum essential medium (MEM) with 15 % FBS.
All treatments and controls were conducted in triplicate, 
and the HT12 v4 Illumina microarray assay was performed 
using pooled biological replicates. There were no technical 
replicates except where noted. Cells were treated in 174-ml 
culture flasks (Nunc A/S) containing the inhibitor dissolved 
in 40 ml DMEM/MEM with 10 % (v/v) foetal bovine serum 
(FBS) per treatment. Negative control flasks contained only 
the FBS-supplemented media. Treatments were 24 h, and 
treatment start time was 24 h after sub-culture. Incubation was 
at 37 °C with 5.0 % CO2. Approximately 1 × 106 cells from 
each treatment were harvested with 0.5 g/L porcine trypsin 
w/v and 0.2 g/L w/v EDTA in Dulbecco phosphate buffer and 
immediately spun down to a cell pellet. The cells were then 
re-suspended in phosphate-buffered saline (PBS) pH 7.4 con-
taining 0.1 % of Sigma protease inhibitor cocktail and then 
re-centrifuged. The resultant cell pellet was then stored in 
LN2 prior to RNA extraction. Array analysis was performed 
in accordance with the manufacturer’s guidance (http://sup-
port.illumina.com/content/dam/illumina-support/documents/
myillumina/3466bf71-78bd-4842-8bfc-393a45d11874/
wggex_direct_hybridization_assay_guide_11322355_a.pdf).
Protein array
Treatment and control solutions each were added directly 
to three culture flasks at 80 % of confluence for 24 h prior 
to harvesting. Cells from each triplicate were pooled after 
the trypsinisation step. Approximately 1 × 106 MDA-
MB-231 or CaLu-1 cells were harvested from the flasks 
using Trypsin–EDTA solution, centrifuged to a pellet and 
protected with 100 µl of Sigma protease inhibitor cocktail. 
A signalling explorer array (SET100) comprising 1358 
antibodies was used to quantify a range of proteins. The 
tests were performed in accordance with the manufacturers’ 
protocols (http://www.fullmoonbio.com/datasheets/Anti-
bodyArrayUserGuide.pdf).
Caveolin‑1 assay
Cells were gown in 12-well plates (Nunc A/S) until at 
approximately 50 % confluence. Media in treated wells was 
replaced with media plus proadifen at a final concentration 
of 100 µM, and the plates were left for 24 h. The plates 
were then washed twice in PBS and re-filled with 2 ml per 
well of Dulbecco’s phosphate buffer containing anti-caveo-
lin-1 conjugated to fluorescein isothiocyanate (FITC). The 
plates were incubated for a further 2 h, washed repeatedly 
with PBS and then scanned in a fluorescence plate reader 
(FL500 BioTek Instruments Inc.).
Statistical treatment
Gene expression raw array data were assessed for quality, 
and outliers removed. Raw data were deposited at the NIH 
Geo database (see Table 1). A total of 47,319 features were 
transformed using a variance stabilising transformation 
method prior to normalisation across all arrays using the 
robust spline normalisation method. Data were filtered to 
Table 1  Sample numbers for the treatments indicate biological rep-
licates
www.ncbi.nlm.nih.gov/geo/
Treatment MDA-MB-231 CaLu-1
Pravastatin 4 3
GSE47461 GSE47458
Proadifen 4 3
GSE47461 GSE47458
Zoledronic acid 4 2
GSM829774 GSE70027
GSM829775
GSM829776
GSM829777
GSM829810
GSM829811
GSM829812
GSM829813
Fatostatin 2 2
GSE70027 GSE70027
Fatostatin and Proadifen 2 2
GSE70027 GSE70027
Control 4 3
GSE47461 GSE47458
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remove data with p values ≥ 0.05, and a further filter was 
applied to remove all genes not within the EMT subset (the 
gene subset was compiled using the Qiagen Profiler PCR 
array EMT gene list and augmented with genes associ-
ated with rafts and caveolae. (SI Table 1). Mean expression 
measures (summarised intensities) are in log base 2. The 
protein assay was performed with technical replicates using 
pooled cells from three replicate flasks. Array data with a 
coefficient of variation <0.1 were removed.
mRNA array data were confirmed by RT-qPCR. Cross-
validation data were available for 70 % of the entire sub-
set using QIAGEN human VEGF signalling array (PAHS-
091Z) and MET array (PAHS-090Z) in combination for 
proadifen and pravastatin treatments in both cell lines 
(8 samples). This additional data showed that in accord-
ance with recent published reviews of validation metadata 
(Wang et al. 2006) there was a high overall correlation 
between the RNA microarray and qRT-PCR results. Subset 
genes appearing in Figs. 1, 2, 3 and 4 are extracted, and 
corresponding PCR data are presented in SI Table 3.
Results
Within the subset of genes normally up-regulated during 
EMT in MDA-MB-231, there were 22 significant up-/down-
regulations between −1.75 and +0.5 log2 fold change (FC), 
and the majority of these genes were up-regulated (Fig. 1). 
In contrast, CaLu-1 cells showed greater sensitivity to the 
inhibitors with 28 affected genes showing responses that 
ranged from −2.60 to +1.7 log2 FC (Fig. 2). Proadifen had 
the greatest effect, shadowed by the statin treatment. Zole-
dronic acid and fatostatin had little effect in CaLu-1 cells 
but did have some effect on the breast line. Within the sub-
set of genes related to signalling, both cells responded to 
the inhibitors with the CaLu-1 line showing clear effects on 
regulation of caveolae-associated proteins such as the non-
receptor kinases FYN and ABL. Pravastatin generally tracked 
but lagged proadifen in CaLu-1. MDA-MB-231 was largely 
unresponsive to the statin and proadifen. CAV1 was down-
regulated in both lines by proadifen with this down-regula-
tion being translated into protein expression only in CaLu-1 
cells (Fig. 5). The protein array analyses showed only down-
regulations in both cell lines with 7 proteins only impacted 
by proadifen in CaLu-1. Significantly, these include the 
receptors for EGF, VEGF, PDGF and androgens (Fig. 6).
Discussion and conclusions
Much research effort has been focussed on the reduction in 
cancer-related morbidity and mortality in long-term statin 
users (Hindler et al. 2006). Statins competitively inhibit 
the HMG-CoA reductase enzyme found at the beginning 
of the mevalonate pathway. They have been implicated in 
pleiotropic effects such as inflammation, immune modula-
tion and autophagy of cancer cells, while epidemiological 
studies suggest a beneficial role in cancer recurrence and it 
has been reported previously that gene expression of can-
cer cells treated with statins in vitro is profoundly altered 
(Garnett and Greenhough 2012). The mevalonate path-
way intermediates geranylgeranyl pyrophosphate (GGPP) 
-2.00-1.00 - 1.00 2.00
BMP1(1/2)
CAMK2N1
CALD1
IGFBP4
AHNAK(3/3)
AHNAK(2/3)
MMP3
VPS13A(4/4)
GNG11
FOXC2
VPS13A(3/4)
WNT5B(2/2)
TMEFF1
SNAI2
VPS13A(2/4)
SNAI3
FN1(2/3)
TCF4
WNT5A
ITGAV
TMEM132A
COL3A1
MDA-MB-231 Genes normally up-regulated 
during EMT  
Proadifen and
Fatostatin
Proadifen
Pravastatin
Fatostatin
Fig. 1  The effects of the treatments on MDA-MB-231 cells. The data 
(p < 0.05) are confined to a subset of genes classically up-regulated 
during EMT. Proadifen and to a lesser degree pravastatin cause some 
significant movements, notably COL3A1 that codes for collagen type 
III alpha 1. Zoledronic acid caused no effects at p < 0.05 in this Ras-
negative cell line
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and farnesylpyrophosphate (FPP) are responsible for the 
isoprenylation of numerous GTPase signal proteins, most 
notably the RhoA superfamily. The signal transduction of 
farnesylated Ras (Casey et al. 1989) and Rho is blocked by 
farnesyl transferase inhibitors that have anticancer effects 
(Oliff 1999).
In CaLu-1, where there was a detectable effect of zole-
dronic acid, there was no overlap in gene response with 
the other treatments, suggesting that a double blockade of 
isoprenylation and Δ-24 oxidoreductase would have the 
greatest impact on cellular status. Zoledronic acid had no 
effect on the transcription of genes within the EMT subset 
in MDA-MB-231, and this is likely to be due to the Ras-
inactive status of this cell line.
SREBP feedback to the transcriptome is truncated by 
fatostatin, and additional cholesterol is not manufactured 
and deployed to the construction of invadopodia or the 
caveolae superstructure. Likewise, inhibition of free cho-
lesterol per se by proadifen or pravastatin will disable the 
cell from forming this new architecture. The combination 
-4 -2 0 2
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AHNAK(3/3)
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IGFBP4
BMP1(1/2)
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MMP2
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WNT5B(2/2)
TCF4
AHNAK(1/3)
TMEM132A
SERPINE1
MMP3
CaLu-1 Genes normally up-regulated in EMT 
Zoledronic
Proadifen and
Fatostatin
Proadifen
Pravastatin
Fatostatin
Fig. 2  The response to the same treatments in CaLu-1 cells where 
significant changes to gene expression can be seen. Zoledronic acid 
displays a modest effect in FOXC2 (transcription factor FKH-14 
associated with EMT) and FN1 (a fibronectin) -2 -1 0 1 2
VEGFA(3/3)
SREBF1(1/3)
VEGFA(2/3)
EGFR(4/4)
FLOT1
SREBF1(3/3)
VEGFB(1/3)
S100A4(1/2)
EBAG9(2/3)
S100A4(2/2)
VEGFB(2/3)
PDGFB(3/3)
ABL1(3/3)
EBAG9(3/3)
INSR
RASA1(1/3)
EGFR(2/4)
PDGFB(2/3)
RASA1(2/3)
ABL1(1/3)
EBAG9(1/3)
CAV1
PDGFB(1/3)
PDGFC
PDGFD(1/2)
PDGFRB
PGRMC2
PGRMC1
ABL1(2/3)
VEGFC
FYN(2/4)
CaLu-1 Signalling genes 
Zoledronic
Proadifen and
Fatostatin
Proadifen
Pravastatin
Fatostatin
Fig. 3  The effects of the treatments on CaLu-1 cells. The data are fil-
tered for significance (p < 0.05) and by the subset of genes associated 
with signalling. X-axis shows log2 fold change. Transcription of FYN 
and ABL1 is reduced; both FYN and ABL proteins mediate transduc-
tion at caveolae. PDGF and PDGF/R are likewise down-regulated. 
The down-regulated genes at the top of the graph are associated with 
caveolae, while the up-regulated genes at the lower part of the graph 
are associated with rafts
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of fatostatin and proadifen is marginally synergistic. A per-
turbation of rafts in MDA-MB-231 is sufficient to inhibit 
EGF/R signalling (Rogers et al. 2010). Caveolae have 
a specific requirement for free cholesterol to intercalate 
with Cav-1 (Murata et al. 1995), while rafts appear able to 
form with cholesterol intermediates and remain functional. 
This is supported by gene knockout mice (DHCR24−/−) 
that cannot complete the Bloch pathway yet remain viable 
(Wechsler et al. 2003) utilising the precursor desmosterol 
for structural and ligand-binding purposes. This suggests 
that a reduction in free cholesterol will adversely affect 
caveolae-based signalling to a greater degree than raft 
signalling.
The MDA-MB-231 line is Ras-inactive and ER-nega-
tive and consequently less vulnerable to inhibition of both 
isoprenylation and hormone stimulation. The results pre-
sented here reflect this status, with Pravastatin and zole-
dronic acid having modest or zero effects, respectively, 
in this cell line. The role of caveolae in lung cancer cells 
is revealed: the mRNA data show a significant down-reg-
ulation of both PDGF and its receptor PDGF/R. This is 
concurrent with a significant reduction in caveolae scaf-
fold CAV1 and associated trafficking proteins FYN, ABL 
and SCAP that mediate the ECM signals once the bilayer 
has been traversed. Down-regulation of ABL is not sub-
ject to losses in translation, and ABL protein is reduced in 
both cell lines and very significantly in CaLu-1 (−50 %). 
Other indicators of pluripotency are affected by the treat-
ments, and the response is cell type specific, with CaLu-1 
displaying more sensitivity to the statin and to proadifen 
compared to MDA-MB-2312. Protein analysis shows that 
the directionality of the gene regulations is indeed trans-
lated to protein expression for some signalling molecules. 
In CaLu-1 these specifically overlap with a number of 
growth factors including PDGF, VEGF and EGF. PDGF, 
PDGF/R (Tiesman and Hart 1993) and VEGF (Kendall 
et al. 1996) are water soluble and thus may be of particu-
lar importance in caveolae-mediated signalling in lung 
cancer (see Figs. 1, 6) where these signals use caveolae to 
access the cell. The treatments also caused a reduction in 
expressed matrix metalloproteinases (FC: MDA-MB-231 
↓0.784; FC: CaLu-1 ↓0.704; SI Table 2), showing that that 
a reduction in cholesterol in both cell lines caused a reduc-
tion in the metastatic phenotype.
Δ-24 DHCR-inhibiting drugs selectively reduce the 
formation of caveolae, and the consequent deprivation 
of those extracellular signals that depend on caveolae for 
transduction causes gene expression to be moved towards 
quiescence. It is possible that those cells forced to main-
tain a more epithelial identity may be unable to re-acquire 
malignant proliferation (Iiizumi et al. 2008; Aguirre-Ghiso 
2007).
Normally, as the cell produces invadopodia, signalling 
associated with invadopodia-localised caveolae will increase; 
as this occurs there may be an autoinductive response by the 
cell-promoting invadopodia. Such a cycle would only rein-
force EMT, while a disruption in this process would serve to 
promote quiescence. This research supports the theory that 
caveolae are a critical conduit for autocrine/paracrine signals 
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MDA-MB-231 Signalling related genes 
Proadifen and
Fatostatin
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Fatostatin
Fig. 4  FYN and ABL1 are up-regulated by fatostatin, while proad-
ifen causes an up-regulation of SCAP, a protein associated with cave-
olae. CAV1 and RASA1 are down-regulated by proadifen. Splice 
variants are numbered x/y, and their identifiers are listed in the sup-
plementary data
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that promote the metastatic phenotype and that their aboli-
tion is beneficial to cellular identity.
Proadifen inhibits several of the cytochrome p450 mono-
oxygenase reactions in a heterogeneous manner (Anders 
and Mannering 1966), but a more specific Δ-24 inhibitor 
may have clinical value in the forced dormancy of dissemi-
nated tumour cells.
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Fig. 5  CAV1 down-regulation 
is mirrored in the CAV-1 protein 
assay only in CaLu-1 cells. 
Expressed protein levels in 
MDA-MB-231 cells are not 
significantly different from the 
control groups. Error bars are 
±SE
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